Bamboocloud has garnered 300 million yuan ($44 million) in a Series C round of financing from Sequoia Capital China and Kunlun Fund, while ImmuneOnco Biopharma has secured $25 million in a Series B round led by Lilly Asia Ventures.
Bamboocloud bags $44m Series C round
Chinese identity and access management (IAM) platform Bamboocloud has garnered 300 million yuan ($44 million) in a Series C round of financing from Sequoia Capital China and Kunlun Fund, a Beijing-based private equity firm focused on TMT (technology, media, telecom) and new consumption, Bamboocloud posted on WeChat on Monday.
The company claims that it is the largest funding in the field of IAM.
Founded in 2009 in Shenzhen, Bamboocloud is active in IAM and cloud-driven application security. It develops accessible software for enterprises to ensure internet security. In addition, Bamboocloud accelerates its business ecosystem toward identity-as-a-service (IDaaS).
The company’s top clients include a clutch of state-owned organisations including National Development and Reform Commission, Sinopec Group, Sinopharm, and China Merchants Bank.
It’s early-stage investors consist of Oriental Fortune Capital, TopoScend Capital, Fortune Capital, and Technology Financial Group, among others.
Lilly Asia leads $25m Series B round in ImmuneOnco
ImmuneOnco Biopharma, an early-stage biopharmaceutical company that aims to develop immunotherapy for tumors, has pocketed $25 million in a Series B round of financing led by Chinese global biomedical venture capital firm Lilly Asia Ventures (LAV).
The round was joined by LYFE Capital, a Sino-US market-focused healthcare fund with $1.3 billion in assets under management. Returning investor Milestone also participated in the fresh funding.
ImmuneOnco will invest the proceeds to support clinical trials.
Located at Zhangjiang Hi-Tech Park in Shanghai, the five-year-old ImmuneOnco has been engaged in new generation cancer immunotherapy products. The flagship platform, Target-Activated NK Cell Therapy, enables to fight against stressed cells such as virally-infected cells and cancer cells.
Before the current round, ImmuneOnco had closed six rounds of fundraising from digital medical investment firm Lang Sheng Investment, Lapam Capital, and Z&H Investment, among others.